Epitalon

Overview

Epitalon (also spelled Epithalon, and sometimes called the AEDG peptide) is a short synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly. It was developed by the Russian gerontologist Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, who described it as the putative active fragment of epithalamin, a peptide preparation originally extracted from the pineal gland. It belongs to a family of "short peptide bioregulators" promoted by the same group.

Epitalon is discussed almost entirely in the context of anti-aging and longevity. The headline claims are that it activates telomerase (the enzyme that maintains telomeres), lengthens telomeres, regulates pineal/melatonin rhythms, and extends lifespan. These are striking claims, and they are widely repeated in commercial and popular writing.

The evidence behind those claims, however, is weak and unevenly distributed. A large share of the supporting studies come from Khavinson's own research group, many are older, small, and methodologically limited, and until recently almost none had been independently replicated. Human data are very sparse, and several high-profile human studies actually used epithalamin (the pineal extract), not the pure synthetic Epitalon tetrapeptide. Epitalon is not an approved drug or supplement in any major jurisdiction.

Epitalon is frequently grouped with other compounds studied in longevity contexts, such as MOTS-c. As with those compounds, the gap between bold mechanistic claims and rigorous human evidence is the central thing to understand.

Chemistry and structure

Epitalon is a linear tetrapeptide (four amino acids) with the sequence:

Ala-Glu-Asp-Gly (one-letter: AEDG)

The peptide is small and highly water-soluble, with two acidic side chains. Khavinson's group has proposed that such short peptides can interact directly with DNA and histone proteins, and a 2020 paper from that group (with Italian collaborators) reported that AEDG can bind linker histones and influence gene expression. As an independent 2025 review notes, the physico-chemical and structural characterization of the peptide remains limited relative to the number of biological-activity claims made about it.

Proposed mechanisms

The mechanisms attributed to Epitalon are best read as hypotheses. They are repeated confidently in secondary sources, but the primary support is largely preclinical and, in several cases, comes from a single group.

Proposed telomerase / telomere mechanism

The most famous claim is that Epitalon reactivates telomerase in cells that normally lack it, increasing expression of the catalytic subunit hTERT and lengthening telomeres.

• The foundational report is Khavinson, Bondarev and Butyugov (2003), who described telomerase activity and telomere elongation in telomerase-negative human fetal fibroblasts exposed to the peptide in culture.
• Because telomere shortening is one biomarker of cellular aging, this finding has been extrapolated, often far beyond the data, into broad anti-aging claims.
• An in-vitro effect on a cell line does not establish that the same thing happens safely or meaningfully in a living human, and telomerase reactivation is also a feature of many cancers, which makes the claim cut both ways rather than being unambiguously beneficial.

Proposed pineal / melatonin mechanism

Epitalon is described as a pineal "bioregulator" that restores melatonin rhythms in aging.

• This idea descends from work on epithalamin, the pineal extract, which was reported to stimulate melatonin in aged animals and some elderly humans.
• Evidence that the pure synthetic Epitalon tetrapeptide does the same is mixed and species-dependent. As summarized in an independent review, melatonin-enhancing effects are reported in some rodent and primate work but were not consistently demonstrated, and some reported "antioxidant" effects may be downstream of melatonin rather than direct actions of the peptide.

Other proposed effects

Preclinical reports also attribute antioxidant, neuroprotective, antimutagenic, and immune-modulating activity to Epitalon, sometimes framed as "epigenetic" regulation of gene expression. These remain preclinical and mechanistically incomplete; a 2025 review explicitly cautioned that it is uncertain whether the proposed pathways are the sole or even the principal mechanisms.

Research and evidence

The evidence base is old, heterogeneous, largely preclinical, and dominated by one research group. The sections below separate in-vitro and animal work from the much thinner human evidence, and flag replication problems throughout.

Single-group dominance and replication

This is the single most important caveat for Epitalon. A very large fraction of the positive literature (telomerase, melatonin, lifespan, and aging-biomarker claims) traces to Khavinson, Anisimov and colleagues and affiliated institutions. For decades this work saw little independent replication, and the relevant Wikipedia article has been flagged for relying heavily on primary sources and possible fringe framing. Independent reviews (including a Cognitive Vitality assessment) specifically cite single-group dominance, small samples, weak controls, and inconsistent methodology as reasons to treat the claims cautiously.

A notable recent exception is an independent 2025 in-vitro study (Al-Dulaimi et al., Brunel University London), which reported that Epitalon increased telomere length in human cell lines: via telomerase upregulation in normal epithelial and fibroblast cells, and via the ALT (alternative lengthening of telomeres) pathway in breast cancer cell lines. This is meaningful as an independent cell-culture signal, but it remains in vitro and does not establish human anti-aging benefit; the cancer-cell finding also reinforces why telomere-lengthening is not automatically "good."

In vitro evidence

• Telomerase / telomeres: Khavinson et al. (2003) and the independent Al-Dulaimi et al. (2025) report telomerase activation and telomere elongation in cultured human cells.
• Gene expression / neurogenesis: Khavinson et al. (2020, Molecules) reported that AEDG increased expression of neuronal markers in cell models and proposed a histone- binding, epigenetic mechanism.
• These are cell-culture findings. They are hypothesis-generating and do not, on their own, demonstrate clinical effects.

Animal evidence

• Lifespan / aging biomarkers: Anisimov, Khavinson et al. (2003) studied Epitalon in female SHR mice given monthly injections from 3 months of age. In that study Epitalon did not change mean lifespan or body weight, but was reported to slow age-related loss of estrous function and to reduce chromosome aberrations in bone-marrow cells. Other reports from the same group describe lifespan extension in rats, mice and fruit flies, but effect sizes and outcomes are inconsistent across studies.
• This animal literature is almost entirely from the originating group, which is a recurring limitation when interpreting the lifespan narrative.

Human evidence (very limited)

• Direct controlled human trials of the pure synthetic Epitalon tetrapeptide are scarce, and much of the "human" evidence cited in popular sources actually involves epithalamin (the pineal extract) rather than Epitalon itself.
• The most-cited human work, for example Korkushko, Khavinson et al. (2011), followed older coronary patients given repeated courses of epithalamin and reported slowed cardiovascular aging and lower mortality over long follow-up. These are from the same research program, were not independently replicated, and concern the extract, so they should not be read as proof for the synthetic peptide.
• There is no robust, independent, modern clinical trial establishing that Epitalon lengthens human telomeres, extends human lifespan, or modifies age-related disease.

Evidence summary

Safety and risks

The safety profile of Epitalon in humans is poorly characterized, and the honest summary is that a lack of reported adverse events reflects a lack of rigorous study, not a demonstration of safety.

• There is no modern, systematic human safety evaluation of the pure synthetic peptide, including no good data on repeated dosing or long-term exposure.
• Material sold as "Epitalon" is a research chemical; its identity, purity, and contaminant profile cannot be assumed to be controlled.
• The telomerase / ALT mechanisms most often cited as benefits are the same pathways exploited by cancers to achieve cellular immortality. This is a theoretical concern that has not been adequately studied in humans and is a reason for caution rather than reassurance.
• Because Epitalon is administered as an injectable peptide in research and unregulated contexts, the usual risks of non-sterile injectable products also apply.

Status and regulation

Epitalon is not an approved medicine, food ingredient, or dietary supplement in the United States, European Union, United Kingdom, or other major jurisdictions. It has not been approved by the FDA or EMA, and it has not completed modern clinical development.

In practice it is sold and handled as a research chemical ("for laboratory research use only"), meaning it is not manufactured, tested, or labeled to pharmaceutical standards, and commercial claims about it are not backed by regulatory review. Note that some related pineal-peptide products developed by the same group have been used or marketed within Russia/CIS settings; that regional history should not be read as approval by Western regulators. Athletes subject to anti-doping rules should be aware that uncharacterized or unapproved peptides can fall under broad prohibitions and should consult current WADA guidance rather than assume permission.

In April 2026 the U.S. FDA removed Epitalon (along with eleven other peptides, including BPC-157, MOTS-c, TB-500 and KPV) from Category 2 of its Section 503A interim bulk-drug list, and scheduled its Pharmacy Compounding Advisory Committee (PCAC) to review several of these peptides, Epitalon among them, at a meeting on July 23–24, 2026. This is an administrative/regulatory review step, not an approval: removal from Category 2 lifts an explicit prohibition flag but does not place a substance on the authorized 503A bulks list, which would require a separate PCAC recommendation and FDA decision. As of this article's date the outcome is pending, and Epitalon remains unapproved as a medicine or supplement.

How it compares

Epitalon is often grouped with other peptides studied in longevity and mitochondrial contexts. The honest comparison is that none of these has robust, replicated human longevity evidence — they differ mainly in proposed mechanism and in how much (still mostly preclinical) data exist.

Key takeaways:

• Different mechanisms, same evidence gap. Epitalon targets telomeres/pineal signaling, MOTS-c is a mitochondrial-derived metabolic regulator, and SS-31 stabilizes mitochondrial membranes. None has demonstrated lifespan extension in humans.
• SS-31 has the most human data, but its trials address defined diseases and have had mixed results; it is not an approved or proven anti-aging therapy.
• Epitalon and MOTS-c remain predominantly preclinical for any longevity claim, and Epitalon carries the added caveats of single-group dominance and extract-vs-peptide confusion.

Common misconceptions

• "Epitalon is a proven anti-aging / longevity drug." It is not. The anti-aging narrative rests on older, mostly single-group, mostly preclinical studies with limited replication and very thin human data.
• "It clearly lengthens human telomeres and extends human lifespan." Telomere lengthening has been shown in cultured cells, and lifespan effects mainly in animals; there is no robust independent human trial demonstrating either outcome in people.
• "Lengthening telomeres / activating telomerase is obviously good." Telomerase and the ALT pathway are also how many cancers maintain telomeres. The same mechanism touted as a benefit is a recognized concern, and the net effect in humans is unestablished.
• "There's strong human clinical evidence from Russian trials." The most-cited human studies often used epithalamin (the pineal extract), not the pure synthetic Epitalon tetrapeptide, came from the originating research program, and were not independently replicated.
• "Independent replication confirms the anti-aging claims." A 2025 independent study did reproduce a telomere-length effect in vitro, which is genuinely notable. But an in-vitro cell-line result is not the same as proven anti-aging benefit in humans.

Community claims & recent evidence

These points address claims circulating in the peptide community (including popular video "masterclasses"), checked against the primary sources we could reach. Treat popular framing as a claim to verify, not a fact — but note the mirror caution too: not locating a supporting citation here does not make a claim false. A great deal of relevant work (paywalled journals, Russian and other regional literature, conference material, clinical practitioner experience, and unpublished or proprietary data) is not indexed in the sources we searched, so several judgements below are limits of what we could reach, not verdicts on the truth.

Verified additions

• [Human] One of the few clinical reports using the pure epitalon peptide (not the epithalamin extract) describes improved retinal bioelectrical and functional activity in a majority (~90%) of patients with retinitis pigmentosa, with a parallel effect in a rat model (Khavinson & Razumovsky, Neuro Endocrinology Letters 2002). It is genuinely a human study of the tetrapeptide, but it is small, open-label, unblinded, and from the originating group — hypothesis-generating, not proof.
• [Animal] In HER-2/neu transgenic mice, monthly subcutaneous epitalon reduced the cumulative number and maximum size of spontaneous mammary tumors versus saline (Anisimov et al., International Journal of Cancer 2002). This is a real anti-tumor signal, but in a genetically engineered mouse model — it does not show epitalon prevents or treats cancer in people.
• [Animal] Epitalon added to larval medium increased adult lifespan by 11–16% in Drosophila melanogaster (Khavinson et al., Mechanisms of Ageing and Development 2000), consistent with the "flies-to-mice" longevity story — while remaining an invertebrate result from the originating group.

Claims we could not corroborate

• Claim: epitalon is "proven beyond a shadow of a doubt" to extend median and maximum lifespan and "shifts the whole survival curve." Assessment: [Animal]/[Hypothesis] no controlled human lifespan data were found in the accessible literature, and the mammalian results we could reach are inconsistent — the originating group's own controlled study reported no change in mean lifespan in female SHR mice (Anisimov et al., Biogerontology 2003); in that study only the maximum lifespan (the tail of the survival curve, ~12%) was extended, which is not the same as shifting the whole survival curve. The positive lifespan findings we could locate are largely invertebrate and single-group, without independent replication that we could trace — which is a gap in what is indexed, not a demonstration that the broader claim is untrue.
• Claim: a "Petravax company in Russia" showed "100%" that epitalon stimulates endogenous interferons and boosts natural-killer-cell activity. Assessment: we could not trace this specific report — neither the company name nor the "100%" figure maps to any study we could locate in the sources we searched. Treat it as an unverified citation pending a locatable source rather than an established finding; the documented immune-modulating claims we did find for the Khavinson program mostly concern thymic peptides (e.g. thymalin) rather than epitalon, though relevant regional or unpublished work may exist beyond our reach.
• Claim: given alongside chemotherapy, epitalon "protects healthy cells from genotoxic damage while sensitizing cancer cells to apoptosis." Assessment: [Hypothesis] we found no primary human (or controlled animal) study demonstrating this selective dual effect in the accessible literature. The cancer data we could reach are limited to reduced spontaneous tumor burden in engineered mice (Anisimov et al., International Journal of Cancer 2002); extrapolating to a chemotherapy "bodyguard" in patients is not something the reachable evidence supports.
• Claim: epitalon "restores hypothalamic insulin and leptin sensitivity," drives mitochondrial biogenesis, and raises ATP output. Assessment: [Hypothesis] we did not find these specific metabolic mechanisms established for epitalon in primary human data we could access; on the current reachable evidence they read as mechanistic narrative rather than measured findings, which is not the same as their being ruled out.
• Claim: it reduces amyloid-beta plaque and protects dopaminergic neurons, making Alzheimer's and Parkinson's "reversible." Assessment: [In vitro]/[Hypothesis] the only relevant primary work we could locate is cell-model gene-expression/neurogenesis data (Khavinson et al., Molecules 2020); we found no clinical evidence in the accessible literature that epitalon treats or reverses neurodegenerative disease, so the "reversible/curable" framing is not something current reachable data support — it should be read as unproven, not as an established cure.

Frequently asked questions

Does epitalon actually work?

It depends entirely on what "work" means. In cultured human cells, epitalon has been reported to activate telomerase and lengthen telomeres — including in one independent 2025 study — so there is a real [In vitro] signal. But for the headline promise, slowing human aging, there is no robust, independent clinical trial showing that epitalon lengthens telomeres, extends lifespan, or changes age-related disease in people [Hypothesis]. The honest answer is that a specific laboratory effect is documented while the anti-aging benefit people actually want remains unproven.

Does epitalon lengthen telomeres in humans?

There is no good human evidence that it does. Telomere lengthening has been shown in cultured cells (Khavinson et al. 2003; independently Al-Dulaimi et al. 2025) [In vitro], and telomere-related lifespan effects have been reported mainly in animals [Animal]. No controlled human trial has demonstrated telomere lengthening in living people [Hypothesis]. An effect on a cell line in a dish does not establish that the same thing happens safely or meaningfully in a human body.

Can epitalon make you live longer?

Not on the current evidence. There is no human lifespan data at all, and mammalian results are inconsistent: the originating group's own controlled study found no change in mean lifespan in female SHR mice, extending only the tail of the survival curve (maximum lifespan +12%, longest-lived tenth +13%) rather than shifting the whole curve (Anisimov et al., Biogerontology 2003) [Animal]. Larger claims that lifespan extension is "proven beyond a shadow of a doubt" are not supported — the positive lifespan findings are largely invertebrate, single-group, and not independently replicated [Animal]/[Hypothesis].

Is epitalon safe, and can it cause cancer?

Its safety in humans is poorly characterized: there is no modern, systematic human safety study, so the absence of reported harms reflects a lack of rigorous study rather than a demonstration of safety [Hypothesis]. On cancer the picture cuts both ways. The very telomerase and ALT pathways promoted as benefits are the same mechanisms many cancers use to become immortal, which is a theoretical concern, not reassurance [In vitro]/[Hypothesis]. Separately, epitalon reduced spontaneous mammary tumors in genetically engineered mice (Anisimov et al., Int. J. Cancer 2002) [Animal] — a real anti-tumor signal in that model, but not evidence that it prevents or treats cancer in people, and claims that it "protects healthy cells while sensitizing cancer cells" during chemotherapy are unsupported [Hypothesis].

Does epitalon improve sleep or restore melatonin?

This is plausible in theory but not well established for the pure peptide. The melatonin-rhythm idea descends from work on epithalamin, the pineal extract, not epitalon itself, and evidence that the synthetic tetrapeptide restores melatonin is mixed and species-dependent — reported in some rodent and primate work but not consistently demonstrated [Animal]. There is no solid controlled human trial showing epitalon improves sleep or melatonin in people [Hypothesis].

Is epitalon FDA-approved or legal to buy?

No, epitalon is not an approved medicine, food ingredient, or dietary supplement in the US, EU, UK, or other major jurisdictions, and it has not completed modern clinical development. It is sold and handled as a research chemical ("for laboratory research use only"), so its identity, purity, and contaminants cannot be assumed to be controlled. In April 2026 the FDA removed epitalon from Category 2 of its Section 503A interim bulk-drug list and scheduled a Pharmacy Compounding Advisory Committee review on July 23–24, 2026; that is an administrative step, not an approval, and as of this article the outcome is pending and epitalon remains unapproved.

Russian research

Much of the evidence for epitalon comes from a single Russian research lineage — the St. Petersburg Institute of Bioregulation and Gerontology (the Khavinson/Anisimov group), which originated the compound. It is surfaced here for completeness and framed honestly for quality; being studied by the originating group is not the same as being independently proven.

• The foundational telomerase claim [In vitro]. In telomerase-negative human fetal fibroblast cell culture, adding the peptide reportedly induced expression of the telomerase catalytic subunit, telomerase enzymatic activity, and telomere elongation, with treated cells making additional divisions beyond the control (Hayflick) limit. This single-group, cell-culture study is the basis of the entire anti-aging narrative (Khavinson VKh, Bondarev IE, Butyugov AA. Bull Exp Biol Med. 2003;135(6):590-592. PMID 12937682; doi 10.1023/a:1025493705728).

• Mean-lifespan null in mammals [Animal]. In the originating group's own controlled study of female Swiss-derived SHR mice given monthly injections from 3 months of age, Epitalon did NOT change food consumption, body weight, or mean lifespan; it did slow the age-related switch-off of estrous function and decrease chromosome aberrations in bone-marrow cells. (The paper does report a smaller effect on the tail of the survival curve — roughly a 12-13% rise in the lifespan of the longest-lived 10% — but the population mean was unchanged.) This is honest counter-evidence from the developers themselves and directly contradicts popular "proven lifespan extension" claims (Anisimov VN, Khavinson VKh, Popovich IG, et al. Biogerontology. 2003;4(4):193-202. PMID 14501183; doi 10.1023/a:1025114230714).

• Invertebrate lifespan [Animal]. In Drosophila melanogaster with the peptide added to the culture medium at the egg-to-larva developmental stage only, an 11-16% increase in adult (imago) lifespan was reported at very low concentrations — an invertebrate, single-group result (Khavinson VKh, Izmaylov DM, Obukhova LK, Malinin VV. Mech Ageing Dev. 2000;120(1-3):141-149. PMID 11087911; doi 10.1016/S0047-6374(00)00217-7).

• Anti-tumor signal in engineered mice [Animal]. In female HER-2/neu transgenic mice given subcutaneous epitalon monthly, the peptide reduced the cumulative number and maximum size of spontaneous mammary tumors and decreased HER-2/neu mRNA expression roughly 3.7-fold versus saline (notably, the comparator peptide Vilon had the opposite, tumor-promoting effect). This is a real anti-tumor signal in a genetically engineered model and does NOT demonstrate cancer prevention or treatment in humans (Anisimov VN, Khavinson VKh, Provinciali M, et al. Int J Cancer. 2002;101(1):7-10. PMID 12209581; doi 10.1002/ijc.10570).

• Retinitis pigmentosa — pure peptide in humans [Human] + [Animal]. An open-label human case series of retinitis pigmentosa patients plus a Campbell-rat model of hereditary retinal degeneration reported improved retinal bioelectric/functional activity, with a parallel retina-preserving effect in the rat model. This is one of the few human reports using the pure epitalon tetrapeptide (rather than the epithalamin extract), but it is small, open-label, unblinded, and single-group (Khavinson V, Razumovsky M, Trofimova S, et al. Neuro Endocrinol Lett. 2002;23(4):365-368. PMID 12195242). The abstract does state a "positive clinical effect in 90% of the cases," but that figure comes from an unblinded, uncontrolled case series with no independent replication — treat the "~90%" as an open-label response rate, not a demonstrated efficacy rate.

• Melatonin rhythm in aged monkeys and elderly people [Animal] + [Human]. In aged rhesus monkeys (Macaca mulatta) and elderly humans, both epithalamin (the extract) AND synthetic epitalon (the tetrapeptide) were reported to recover nocturnal melatonin release and normalize the melatonin circadian rhythm in blood plasma. Note that testing the extract and the peptide together is exactly the extract-vs-peptide conflation to watch for. Russian-language (Korkushko OV, Lapin BA, Goncharova ND, Khavinson VKh, Shatilo VB, et al. Adv Gerontol (Usp Gerontol). 2007;20(1):74-85. PMID 17969590).

• 15-year cardiovascular follow-up — the EXTRACT, not the peptide [Human]. In coronary patients, 39 given biannual courses of EPITHALAMIN (the pineal EXTRACT) plus basic therapy versus 40 on basic therapy alone over 3 years, long-term follow-up reported decelerated cardiovascular aging, normalized melatonin/carbohydrate/lipid parameters, and lower overall mortality in the epithalamin group. Critically, this used epithalamin, the crude extract — NOT the pure synthetic epitalon tetrapeptide — and it has not been independently replicated (Korkushko OV, Khavinson VKh, Shatilo VB, Antonyk-Sheglova IA. Bull Exp Biol Med. 2011;151(3):366-369. PMID 22451889; doi 10.1007/s10517-011-1332-x).

Regulatory fact (extract, not peptide). Two things must be kept strictly separate. EPITHALAMIN — the crude bovine pineal peptide EXTRACT (a complex of peptides <10 kDa) — is a registered medicine in Russia; the developer's own open-access review states it was created in 1990 with registration certificate No. 90/250/6 and is manufactured in Russia by Samson-Med LLC (St. Petersburg) as a biogenic regulator (Khavinson VKh. Klin Med. 2020;98(3):165-177; open full text on CyberLeninka: https://cyberleninka.ru/article/n/lekarstvennye-peptidnye-preparaty-proshloe-nastoyaschee-buduschee (opens in a new tab)). This is a regulatory/historical fact, not proof of efficacy, and it is authored by the compound's own developer — use it only as the registration anchor, not as independent evidence. By contrast, EPITALON / EPITHALON — the pure synthetic tetrapeptide Ala-Glu-Asp-Gly, which is what this article is about — is a separate compound sold as a research chemical / bioregulator; no verifiable Russian marketing-authorization registration number for the pure synthetic tetrapeptide itself could be found. Treat any claim that "epitalon is a registered Russian drug" as unverified: it is the extract (epithalamin) that carries the registration, not the synthetic peptide.

Unverifiable popular claims. Several widely repeated claims resolve to no indexed primary source: the assertion that a "Petravax company in Russia showed 100% that epitalon stimulates endogenous interferons and boosts NK-cell activity" traces to no verifiable paper; and claims that epitalon "restores hypothalamic insulin/leptin sensitivity," "drives mitochondrial biogenesis / raises ATP," or makes Alzheimer's/Parkinson's "reversible" have no verifying primary study and remain mechanistic narrative [Hypothesis]. Russian-language sources describe these effects, but no independently verifiable citation was found.

Quality bottom line. This literature is small, older, single-group (nearly every efficacy study traces to Khavinson/Anisimov and their institute — even the 2020 "evidence" review is by the developer), and largely under-replicated outside Russia. The strongest positive lifespan data are invertebrate or in vitro; the mammalian mean-lifespan result is null; the strongest "human" evidence used the epithalamin EXTRACT rather than the pure peptide; and human sample sizes are tiny. Russian registration of the extract is a regulatory fact, not proof of efficacy, and does not transfer to the synthetic epitalon peptide. Being studied is not being proven.